Core Viewpoint - The appointment of Mr. Lu Ying as the Chief Financial Officer of Weisheng Pharmaceutical-B (02561.HK) is a strategic move aimed at enhancing the company's financial management and investor relations capabilities [3]. Group 1: Appointment Details - Weisheng Pharmaceutical-B announced the appointment of Mr. Lu Ying as CFO effective from October 13, 2025 [3]. - Mr. Lu Ying, aged 41, has over 19 years of financial management experience [3]. Group 2: Previous Experience - Prior to joining Weisheng Pharmaceutical, Mr. Lu served as CFO at Weimou Biotechnology (Zhejiang) Co., Ltd. from August 2021 to October 2025, focusing on corporate financing and investor relations [3]. - He held the position of Financial Director at Allergan Information Consulting (Shanghai) Co., Ltd. from August 2020 to August 2021, overseeing financial management and strategic planning [3]. - Mr. Lu worked at Bayer A.G. in various financial management roles from September 2010 to August 2020, with his last position being CFO of Bayer Healthcare, responsible for overall financial management in Hong Kong [3]. - Earlier in his career, he was a Senior Accountant at PwC from August 2006 to February 2010 [3]. Group 3: Educational Background - Mr. Lu obtained a Bachelor's degree in Economic and Trade English from Shanghai University of Finance and Economics in June 2006 [3].

维昇药业-B(02561)发布公告，陆楹已获委任为公司首席财务官，自2025年10月13日起生效。 ...

格隆汇10月13日丨维昇药业-Ｂ(02561.HK)宣布，陆楹已获委任为公司首席财务官，自2025年10月13日 起生效。 ...

Core Viewpoint - Vison Pharmaceutical-B (02561) announced the appointment of Lu Ying as the Chief Financial Officer, effective from October 13, 2025 [1] Group 1 - Lu Ying has been appointed as the Chief Financial Officer of Vison Pharmaceutical-B [1]

陸先生於2006年6月自上海財經大學取得經貿英語文學學士學位。 董事會謹此熱烈歡迎陸先生履新。 承董事會命 維昇藥業 執行董事兼首席執行官 盧安邦先生 VISEN Pharmaceuticals 維昇藥業 （於開曼群島註冊成立的有限公司） （股份代號：2561） 委任首席財務官 維昇藥業（「本公司」及其附屬公司「本集團」）董事（「董事」）會（「董事會」）欣然宣 布陸楹先生（「陸先生」）已獲委任為本公司首席財務官，自2025年10月13日起生 效。 陸楹先生，41歲，擁有逾19年的財務管理經驗。加入本集團之前，陸先生自2021 年8月至2025年10月擔任維眸生物科技（浙江）有限公司首席財務官（該公司是一 家開發眼部疾病創新療法的臨床階段製藥公司），負責統籌管理企業融資、投資 者關係及財務管理。在此之前，彼自2020年8月至2021年8月擔任艾爾建信息諮詢 （上海）有限公司財務總監，負責財務管理、戰略規劃、內部控制及合併後整合。 陸先生自2010年9月至2020年8月在Bayer A.G.集團內擔任多個財務管理職位，其 在此擔任的最後職位為拜耳醫療保健有限公司首席財務官，主要負責拜耳在香港 醫療保健業務的整體財 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 維昇藥業 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02561 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 USD | | | 50,000 | 本月底法定/ ...

Core Viewpoint - Vison Pharma-B (02561) has seen a significant stock price increase, currently trading at 44.68 HKD, reflecting a rise of 2.81% [1] Group 1: Company Developments - The fastest R&D progress for Vison Pharma is with Long-acting Growth Hormone, expected to be approved for domestic market launch in the second half of 2025, potentially becoming the third long-acting growth hormone available in China [1] - The company has two unique products: Napeptide and Parapeptide, with the latter anticipated to submit a market application by the end of 2025 [1] - In June, Vison Pharma partnered with WuXi Biologics to advance localized production, aiming to provide cost-effective and high-value products to meet domestic clinical needs [1] - In July, Vison Pharma collaborated with Anke Bio (300009) to jointly promote product commercialization, indicating promising future market prospects [1]

Core Viewpoint - Vison Pharma-B (02561) has seen a stock price increase of nearly 4%, currently trading at 44.68 HKD, driven by positive developments in its product pipeline and strategic partnerships [1] Group 1: Product Development - The fastest progressing product in Vison Pharma's pipeline is Long-Acting Growth Hormone, expected to receive domestic approval in the second half of 2025, potentially becoming the third long-acting growth hormone approved in China [1] - The company currently has two unique products: Napeptide and Parapeptide, with the latter anticipated to submit a market application by the end of 2025 [1] Group 2: Strategic Partnerships - In June, Vison Pharma entered into a collaboration with WuXi Biologics to advance localized production, aiming to provide cost-effective and high-value products to meet domestic clinical needs [1] - In July, the company partnered with Anke Bio to jointly promote the commercialization of its products, indicating a promising market outlook [1]

Core Insights - The Hong Kong pharmaceutical market has shown a structural trend since 2025, with the innovative drug sector becoming a focal point for investment due to its transition to profitability and international expansion [1][2] Industry Overview - In the first half of 2025, 149 Hong Kong-listed pharmaceutical companies reported a 29.7% year-on-year increase in net profit attributable to shareholders, with 36 innovative drug companies generating revenues of 28.5 billion yuan, marking a 15.8% growth [1] - The innovative drug sector has transitioned from a "research and development phase" to a "commercialization phase," driven by companies like BeiGene and Innovent Biologics, which have validated their commercialization capabilities [2] - The current market sentiment favors "high cost-performance" targets, with a focus on companies that have stable R&D pipelines and mature commercialization systems [2] Investment Opportunities - The innovative drug sector is characterized by "high certainty and high elasticity," with increased market rotation and investment interest in companies with strong performance and growth potential [2][3] - Companies with differentiated innovation capabilities and global commercialization potential are recommended for investment, as they are expected to experience rapid revenue growth and profitability [3] - The market is actively seeking investment targets that combine "valuation recovery and product realization," with a focus on companies like Vison Pharma, which is positioned in the growth hormone market [4][5] Company Spotlight: Vison Pharma - Vison Pharma is recognized as an undervalued innovative drug company with both valuation recovery and growth potential, focusing on the growth hormone market [5][6] - The company's core product, Lonapegsomatropin, is expected to be commercialized in China, with significant market potential and a strong clinical validation track record [6][7] - Vison Pharma has established strategic partnerships to enhance its commercialization capabilities, including exclusive promotion agreements and local production arrangements [7][8] Market Positioning - Vison Pharma's upcoming product launch is crucial for its value realization, with the potential to capture a significant market share in the long-acting growth hormone segment [6][9] - The company is well-positioned in a "value gap" state, avoiding the risks associated with early-stage biotech while not being assigned the high valuations typical of mature pharmaceutical companies [9]

Group 1 - The core point of the article highlights that the total market capitalization of Chinese biotech stocks listed in Hong Kong has increased by 154% year-to-date, significantly outperforming the Hang Seng Index's 34% rise, indicating a major shift in market recognition of local pharmaceutical companies' innovation capabilities [1] - The report anticipates that the Federal Reserve's accelerated interest rate cuts will enhance risk appetite, directing funds towards growth sectors such as Chinese biotechnology [1] - However, the performance of individual stocks is expected to depend on company fundamentals, including commercialization execution and innovation research progress [1] Group 2 - The report expresses optimism for companies with short-term catalysts, specifically naming Kangfang Biotech (09926), Nuo Cheng Jian Hua (09969), and others as potential beneficiaries [1] - Additionally, it assigns an "outperform" rating to Weisheng Pharmaceutical-B (02561) and Zai Lab (09688) [1]